A factor involved in the apoptosis cascade, caspase-6, has been identified as a target for interfering with the replication of coronaviruses in work by The University of Hong Kong scientists and their collaborators.

Griffith University has presented new compounds reported to be useful for the treatment of respiratory syncytial virus (RSV), influenza A, influenza B, influenza C and parainfluenza virus infections.

The University of Michigan, the University of Illinois and the Penn State Research Foundation have presented rifamycin derivatives acting as RNA polymerase (bacterial) inhibitors reported to be useful for the treatment of tuberculosis.

Listeria monocytogenes causes sporadic outbreaks of infection globally through contaminated food and is fatal in immunocompromised individuals.

Gilead Sciences has presented substituted pyridotriazine compounds reported to be useful for the treatment of HIV infections.

Staphylococcus aureus is the most common bacterium recovered in orthopedic infections. Exebacase and CF-296 (ContraFect) are known to be anti-staphylococcal lysins with activity against S. aureus.

Brii Biosciences has disclosed prodrugs of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) reported to be useful for the treatment of HIV infection.

Researchers from Bioland Laboratory (Guangzhou Regenerative Medicine and Health - Guangdong Laboratory) and the University of Groningen have generated a series of novel biphenyl-benzamides as inhibitors of cell division protein FtsZ with encouraging antibacterial activity.

Metabrain Research and Shanghai Visonpharma have presented macrocyclic Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of hepatitis B virus (HBV), HCV, HIV and influenza virus infections, and cancer.

Scientists from the University Grenoble Alpes in France and colleagues have recently identified a promising drug candidate with broad-spectrum activity against apicomplexans using a drug repurposing strategy.